Selecta Biosciences, Inc. (1S7.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR

1.6105

+0.0290

(+1.83%)

As of 04:08PM CET. Market open.

Advertisement

Loading interactive chart...

Benzinga
Analyst Says Selecta Biosciences' Gout Candidate Can Potentially Raise The Bar On Several Fronts
Canaccord Genuity has increased the price target for Selecta Biosciences Inc (NASDAQ: SELB) from $9 to $10 while maintaining the Buy rating ahead of the upcoming data from two Phase 3 studies of SEL-212 for chronic refractory gout. The analyst expects positive top-line data in 1Q23 for SEL-212. While many will likely compare the results to Horizon Therapeutics PLC's (NASDAQ: HZNP) Krystexxa and the various immunomodulating combinations, Canaccord sees SEL-212 as a step ahead in the gout treatmen
Simply Wall St.
Positive week for Selecta Biosciences, Inc. (NASDAQ:SELB) institutional investors who lost 34% over the past year
Every investor in Selecta Biosciences, Inc. ( NASDAQ:SELB ) should be aware of the most powerful shareholder groups...
American City Business Journals
The Petri Dish: Moderna looks at new price tag for Covid vaccine
Moderna Inc. (Nasdaq: MRNA) is considering hiking the price of its Covid-19 vaccine up by up to 400%.